期刊
STATISTICS IN BIOPHARMACEUTICAL RESEARCH
卷 3, 期 3, 页码 476-487出版社
AMER STATISTICAL ASSOC
DOI: 10.1198/sbr.2011.10070
关键词
Clinical endpoint; Clinical meaningfulness of results; Dichotomization; Loss of power; Responders
Ideally, a clinical trial should be able to demonstrate not only a statistically significant improvement in the primary efficacy endpoint, but also that the magnitude of the effect is clinically relevant. One approach to address this question, often proposed by clinical societies and regulatory guidance, is a responder analysis, in which a continuous primary efficacy measure is dichotomized into responders and nonresponders. This article represents a Pharmaceutical Research and Manufacturers of America (PhRMA) position on responder analyses. With respect to demonstration of the existence of a treatment effect, we find that the well-known loss of statistical power associated with a responder analysis outweighs any real or perceived benefits of this approach. However, between-group comparisons of the percentages of responders can play a role in the assessment and reporting of the clinical meaningfulness of the treatment effect.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据